Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer

Season 5, Episode 48,  Oct 07, 2021, 07:34 PM

Dr. Moore discusses the basis for studying the combination of VS-6766 and defactinib in recurrent low-grade serous ovarian cancer, data that has been generated with the combination from the phase 1/2 FRAME trial, and the potential role for the combination in clinical practice.